COMMUNIQUÉS West-GlobeNewswire

CARBIOS announces changes to its governance and reaffirms its strategic objectives
21/03/2025
The Board of Directors has appointed Isabelle PARIZE as its Chairwoman and Vincent KAMEL as Chief Executive Officer with immediate effect CARBIOS reaffirms its objective of building its PET biorecycling plant in [...]
CARBIOS annonce une évolution de sa Gouvernance et réaffirme ses objectifs stratégiques
21/03/2025
Le Conseil d’administration nomme Isabelle PARIZE en qualité de Présidente du Conseil d'administration et Vincent KAMEL en tant que Directeur général avec effet immédiat. CARBIOS réaffirme son objectif de construire son [...]
Prostadine Reviews: Is It Safe And Legit For Prostate Health? Ingredients, Benefits, And Side Effects!
21/03/2025
TALLMADGE, Ohio, March 21, 2025 (GLOBE NEWSWIRE) -- Prostadine is a healthy dietary drink designed to support prostate health naturally. It contains natural ingredients that work in harmony to remove the toxic buildup [...]
Prime Biome Reviews: A Comprehensive Review of the Revolutionary Skin and Gut Health Supplement
21/03/2025
ST. PETERSBURG, Fla., March 21, 2025 (GLOBE NEWSWIRE) -- Prime Biome constitutes a revolutionary probiotic supplement which offers simultaneous benefits to skin and gut health to enhance body wellness throughout both [...]
Lipozem Reviews (2025): Consumer Reports on Lipozem Weight Loss Formula
21/03/2025
LAKELAND, Fla., March 21, 2025 (GLOBE NEWSWIRE) -- Lipozem is reshaping the weight loss arena, which has long been saturated with countless diets, grueling exercise regimens, and expensive medications. Rather than [...]
UCB Convening Notice to the General Meeting of the Shareholders 2025
21/03/2025
CONVENING NOTICE TO THE GENERAL MEETING OF SHAREHOLDERS The Board of Directors invites the shareholders to the ordinary general meeting of the shareholders (the “ General Meeting ”) which will be held on Thursday, 24 [...]
UCB Convocation à l'Assemblée Générale des Actionnaires 2025
21/03/2025
CONVOCATION A L’ASSEMBLEE GENERALE DES ACTIONNAIRES Le Conseil d’administration invite les actionnaires à l’assemblée générale ordinaire des actionnaires (« l’Assemblée Générale ») qui se tiendra le jeudi 24 avril 2025 [...]
Driven by its Pharmaceutical Activities, Roquette's 2024 Results Demonstrate the Resilience of its Integrated Business Model
21/03/2025
Driven by its Pharmaceutical Activities, Roquette's 2024 Results Demonstrate the Resilience of its Integrated Business Model Commercial performance in line with a market which remains below historical levels. 2024 [...]
Portés par ses activités pharmaceutiques, les résultats 2024 de Roquette démontrent la résilience de son modèle intégré
21/03/2025
Portés par ses activités pharmaceutiques, les résultats 2024 de Roquette démontrent la résilience de son modèle intégré Performances commerciales en ligne avec un marché qui reste en deçà des niveaux historiques. [...]
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G)
21/03/2025
Novartis receives third FDA approval for oral Fabhalta ® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G) Phase III study showed sustained proteinuria reduction at one year with favorable [...]
Oculis Publishes Notifications of Transactions by Person Discharging Managerial Responsibilities
20/03/2025
ZUG, Switzerland, March 20, 2025 (GLOBE NEWSWIRE) -- The attached notifications relate to trades entered into by a PDMR of the Company pursuant to a 10b5-1 trading plan, in accordance with Rule 10b5-1(c)(1) of the [...]
vTv Therapeutics Announces 2024 Fourth Quarter and Full Year Financial Results and Provides Corporate Update
20/03/2025
Clinical hold lifted for late stage cadisegliatin program for diabetes CATT1 Phase 3 trial in patients with type 1 diabetes (T1D) expected to resume Q2 2025 Strengthens commercial leadership with appointment of Martin [...]
GENFIT Announces Completion of Non-dilutive Royalty Financing Agreement with HCRx and Results of Repurchase Offer to 2025 OCEANEs holders
20/03/2025
GENFIT completes a royalty financing of up to €185 million with HCRx after unanimous OCEANE bondholder approval, triggering a €130 million upfront payment with potential for an additional €55 million upon achieving near [...]
GENFIT annonce le closing du royalty financing avec HCRx et les résultats de l’Offre de Rachat aux porteurs d’OCEANEs 2025
20/03/2025
GENFIT a finalisé la mise en œuvre d’un royalty financing avec HCRx d’un montant maximum de 185 millions d'euros à la suite de l'approbation unanime des obligataires des OCEANEs 2025. Ce closing a déclenché un premier [...]
BioAge Labs Reports Full Year 2024 Financial Results and Provides Business Updates from the Fourth Quarter of 2024
20/03/2025
Advancement of oral, brain-penetrant NLRP3 inhibitor BGE-102, with initial clinical data expected 2H25 Progression of preclinical next-generation APJ agonists for obesity New platform partnerships with Novartis and [...]
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Financial Officer
20/03/2025
WALTHAM, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven [...]
BioRestorative Therapies to Report 2024 Financial Results and Host Conference Call on March 27, 2025
20/03/2025
MELVILLE, N.Y., March 20, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ) , a clinical stage regenerative medicine innovator focused on stem cell- [...]
Emergent BioSolutions New Hire Equity Grant Under NYSE Rule 303A.08
20/03/2025
GAITHERSBURG, Md., March 20, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS), a leading public health company that delivers protective and life-saving solutions to communities across the world, today [...]
Context Therapeutics Reports Full Year 2024 Operating and Financial Results
20/03/2025
CTIM-76 first patient dosed in January 2025 Cash and cash equivalents of $94.4 million as of December 31, 2024 Company expects its cash and cash equivalents will continue to fund operations into 2027 PHILADELPHIA, March [...]

Pages